Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Signs On For Sangamo’s Hemophilia A Gene Therapy

Executive Summary

Pfizer has turned again to external expertise among US biotechs to find a potential gene therapy for hemophilia A, to add to its two-year collaboration with Spark Therapeutics on a gene therapy for hemophilia B, and beating off strong competition from other suitors in the process.

You may also be interested in...

Pfizer Advances Duchenne Drug As It Prioritizes Gene Therapy

High value deal with Bamboo Therapeutics starts to come to fruition with start of small study in Duchenne muscular dystrophy, which aims at underlying cause as opposed to symptoms of disease.

Pfizer’s Goettler On What Partners Look For In Orphan Drug Deals

Michael Goettler, Pfizer's global president, rare disease global innovative pharma business, offers tips to Korean orphan drug developers on reaching out to potential partners successfully and what Pfizer is looking for in rare disease deals.

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts